Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crenigacestat (Primary) ; Samotolisib (Primary) ; Abemaciclib; Carboplatin; Cisplatin; Gemcitabine; Taladegib
  • Indications Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Lymphoma; Male breast cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 16 Sep 2022 Results reporting on group 2 of 5, published in the Cancer Chemotherapy and Pharmacology
    • 08 Mar 2021 Results (data cutoff date: 2 Jul 2019) assessing safety and tolerability of crenigacestat combined with different agents published in the Investigational New Drugs
    • 02 Mar 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top